January 5, 2012: GlycoMimetics Announces Two Key Leadership Promotions

December 13, 2011: Progress of GlycoMimetics' Novel Compounds Highlighted at 2011 Annual Meeting of the American Society of Hematology

October 11, 2011: GlycoMimetics and Pfizer Enter into Licensing Agreement for Drug Candidate Currently in Development to Treat Patients Experiencing Vaso-occlusive Crisis Associated with Sickle Cell Disease

December 7, 2010:  GlycoMimetics Announces Data Presentations on Lead Compound at American Society of Hematology Annual Meeting

September 28, 2010:  Blood Publishes Pre-Clinical Data on GlycoMimetics, Inc. Lead Compound in Sickle Cell Disease Model

July 14, 2010:  Key GlycoMimetics Patents Issue in the U.S.

June 24, 2010:  GlycoMimetics Initiates Phase 2 Clinical Trial of Lead Candidate GMI-1070 in Sickle Cell Patients and FDA Grants GMI-1070 Fast Track Designation for Treatment of Vaso-Occlusive Crisis of Sickle Cell Disease

December 7, 2009: GlycoMimetics Announces Two Oral Presentations on Lead Drug Candidate GMI-1070 at American Society of Hematology Annual Meeting

October 20, 2009: GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round

September 2, 2009: GlycoMimetics, Inc. Announces Commencement of Pilot Study in Patients of Lead Drug Candidate for Vaso-Occlusive Crisis of Sickle Cell Disease

August 17th, 2009: GlycoMimetics, Inc. Awarded NIH Grant to Study Drug Candidate in Diabetes

July 24th, 2009: Nature Reviews: Drug Discovery Article Describes Design of Glycomimetic Compounds and Newly "Druggable" Disease Targets

May 28th, 2009: Dana-Farber Cancer Institute Presents Results of GlycoMimetics’ Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting

March 26th, 2009: GlycoMimetics, Inc. Completes Phase 1 Clinical Studies of Lead Drug Candidate; GMI-1070 Awarded Orphan Drug Designation by the FDA.

December 8th, 2008: GlycoMimetics, Inc. Selected to Present Preclinical Data on Lead Drug Candidate at 50th Annual Meeting of the American Society of Hematology.

September 5th, 2008: GlycoMimetics, Inc. Commences Phase 1 Clinical Trial of Lead Drug Candidate.

December 9th, 2007: GlycoMimetics Presents Results of Lead Compound in Animal Models of Vaso-Occlusive Crisis at ASH.

July 19th, 2007: GlycoMimetics Highlights Advances in Lead Drug Candidate at International Conference.

September 2nd, 2005: GlycoMimetics to Present New Data on Lead Compounds at International Symposium.

Company Events

GlycoMimetics is Proud to Recognize Rare Disease Day USA — On February 29, 2012, the National Organization for Rare Disorders (NORD) is sponsoring a grassroots day of international advocacy to raise awareness about the global health challenge presented by rare diseases. Held annually on the last day of February, Rare Disease Day has been recognized in over 60 countries around the world since 2008, when it was first observed in Europe by the European Rare Disease Organization (EURORDIS). Since May of 2009, NORD and EURORDIS have collaborated in a strategic partnership to achieve greater awareness and patient advocacy, as well as amplified influence in international public policy.

The official slogan of this year’s Rare Disease Day is "Rare but Strong Together," emphasizing the theme of solidarity among the patients, professionals, and family members involved in combating rare diseases. As a company developing small molecule drugs targeting areas of unmet clinical needs with a focus on rare diseases, GlycoMimetics is proud to support Rare Disease Day. GlycoMimetics is a member of the NORD Corporate Council and is pleased to share information about the company’s current clinical program for patients with Vaso-occlusive Crisis of Sickle Cell Disease via the NORD website.

To take action and learn more about Rare Disease Day, visit rarediseaseday.us.